COPD(Chronic Obstructive Pulmonary Disease)
Conditions
Interventions
Transdermal Tulobuterol (0.5mg, 1mg, 2mg)
Sponsors
Kanazawa Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patient who was diagnosed as COPD. FEV1/FVC level is within 70% after 15 minutes to one hour used the bate2 agonist on respiratory function test that it was performed eight weeks ago from two weeks, and FEV1 level is within 80% more than 30%. 2)Patient that there is sustained dyspnea, and a symptom maintains the same. 3)40 years old and more than it, sex no object. 4)Smoker or patient with the smoking history. 5)No object according to a thing of hospitalization / an outpatient, but do not change the state, during study.
Exclusion criteria
Exclusion criteria: 1)Patient of the symptom that bronchial asthma is main. 2)Patient who takes oral corticosteroid. 3)Patient who uses home oxygen therapy. 4)Patients with a history of hypersensitivity to Tulobuterol. 5)Patient who was considered ineligible to use transdermal Tulobuterol in a patient having skin diseases such as atopic dermatitis. 6)Patient who was considered ineligible to use bata2 agonist in a patient complicated with hyperthyroidism, hypertension, heart disease and diabetes mellitus. 7)Woman who are pregnant or breast feeding, and woman of childbearing potential. 8)Patient who was considered ineligible by the investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Most Graph Lung volumes | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of QOL Respiratory function test Dyspnea Clinical symptom Safe evaluation | — |
Countries
Japan
Contacts
Public ContactHirohisa Toga
Kanazawa Medical University Hospital Respiratory Medicine
Outcome results
None listed